Young-Min Park1, Amy C Keller2, Shauna S Runchey2, Benjamin F Miller3, Wendy M Kohrt4, Rachael E Van Pelt4, Chounghun Kang5, Catherine M Jankowski6, Kerrie L Moreau7. 1. Department of Medicine, Division of Geriatric Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 2. Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 3. Department of Health and Exercise Science, Colorado State University, Fort Collins, CO, USA. 4. Department of Medicine, Division of Geriatric Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; VA Eastern Colorado Health Care System, Geriatric Research Education and Clinical Center (GRECC), Denver, CO, USA. 5. Department of Physical Education, Inha University, Incheon, South Korea. 6. Department of Medicine, Division of Geriatric Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 7. Department of Medicine, Division of Geriatric Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; VA Eastern Colorado Health Care System, Geriatric Research Education and Clinical Center (GRECC), Denver, CO, USA. Electronic address: Kerrie.Moreau@ucdenver.edu.
Abstract
OBJECTIVES:Menopause and decline in estradiol (E2) may contribute to sarcopenia (i.e., age-related decline in muscle mass and strength) in women. E2 may directly impact skeletal muscle protein breakdown via estrogen receptor (ER) signaling, primarily ERα. It is not yet known whether: 1) E2 regulates pathways of skeletal muscle protein breakdown; 2) E2-mediated changes in protein breakdown markers are associated with ERα activation and insulin sensitivity; and 3) the effects of E2 on protein breakdown markers differ by increasing time since menopause. STUDY DESIGN: We studied 27 women who were ≤6 years past menopause (early postmenopausal, EPM; n = 13) or ≥10 yearspast menopause (late postmenopausal, LPM; n = 14). Fasted skeletal muscle samples were collected following 1 week of transdermal E2 or placebo treatment in a randomized cross-over design. MAIN OUTCOME MEASURES: We analyzed for cytosolic protein content of the: 1) structural proteins myosin heavy chain (MHC) and tropomyosin; and 2) protein regulatory markers: protein kinase B (Akt), muscle-specific ring finger protein1 (MuRF1), atrogin1, and forkhead box O3 (FOXO3) using Western blot. RESULTS: In response to acute E2, FOXO3 activation (dephosphorylation) and MuRF1 protein expression decreased in EPM but increased in LPM women (p < 0.05). ERα activation was not associated with these protein breakdown markers, but FOXO3 activation tended to be inversely correlated (r = -0.318, p = 0.065) to insulin sensitivity. CONCLUSIONS: These preliminary studies suggest the effects of E2 on skeletal muscle protein breakdown markers were dependent on time since menopause, which is consistent with our previous study on insulin sensitivity.
RCT Entities:
OBJECTIVES: Menopause and decline in estradiol (E2) may contribute to sarcopenia (i.e., age-related decline in muscle mass and strength) in women. E2 may directly impact skeletal muscle protein breakdown via estrogen receptor (ER) signaling, primarily ERα. It is not yet known whether: 1) E2 regulates pathways of skeletal muscle protein breakdown; 2) E2-mediated changes in protein breakdown markers are associated with ERα activation and insulin sensitivity; and 3) the effects of E2 on protein breakdown markers differ by increasing time since menopause. STUDY DESIGN: We studied 27 women who were ≤6 years past menopause (early postmenopausal, EPM; n = 13) or ≥10 years past menopause (late postmenopausal, LPM; n = 14). Fasted skeletal muscle samples were collected following 1 week of transdermal E2 or placebo treatment in a randomized cross-over design. MAIN OUTCOME MEASURES: We analyzed for cytosolic protein content of the: 1) structural proteins myosin heavy chain (MHC) and tropomyosin; and 2) protein regulatory markers: protein kinase B (Akt), muscle-specific ring finger protein1 (MuRF1), atrogin1, and forkhead box O3 (FOXO3) using Western blot. RESULTS: In response to acute E2, FOXO3 activation (dephosphorylation) and MuRF1 protein expression decreased in EPM but increased in LPM women (p < 0.05). ERα activation was not associated with these protein breakdown markers, but FOXO3 activation tended to be inversely correlated (r = -0.318, p = 0.065) to insulin sensitivity. CONCLUSIONS: These preliminary studies suggest the effects of E2 on skeletal muscle protein breakdown markers were dependent on time since menopause, which is consistent with our previous study on insulin sensitivity.
Authors: R I Pereira; B A Casey; T A Swibas; C B Erickson; P Wolfe; R E Van Pelt Journal: J Clin Endocrinol Metab Date: 2015-10-01 Impact factor: 5.958
Authors: Trevor N Stitt; Doreen Drujan; Brian A Clarke; Frank Panaro; Yekatarina Timofeyva; William O Kline; Michael Gonzalez; George D Yancopoulos; David J Glass Journal: Mol Cell Date: 2004-05-07 Impact factor: 17.970
Authors: G Biolo; P Tessari; S Inchiostro; D Bruttomesso; L Sabadin; C Fongher; G Panebianco; M G Fratton; A Tiengo Journal: Am J Physiol Date: 1992-11
Authors: Ryan Janjuha; Diane Bunn; Richard Hayhoe; Lee Hooper; Asmaa Abdelhamid; Shaan Mahmood; Joseph Hayden-Case; Will Appleyard; Sophie Morris; Ailsa Welch Journal: Nutrients Date: 2020-05-18 Impact factor: 5.717
Authors: Kate A Wickham; Line B Nørregaard; Mikkel Oxfeldt; Stephen S Cheung; Lasse Gliemann; Mette Hansen; Ylva Hellsten Journal: Front Cardiovasc Med Date: 2022-02-10